EXELIXIS INC

Exelixis (EXEL) gains 1.13% as shares rise to $64.53, staying above its 200‑day MA and near a 52‑week high—solid liquidity, a strong oncology pipeline, and strategic pharma alliances suggest upside potential, but investors should watch for clinical …

Exelixis (EXEL) trades near its 200‑day MA with modest gains, driven by a robust small‑molecule cancer pipeline and strategic pharma alliances.

Exelixis (EXEL) stocks are near a 52‑week high, driven by a strong oncology pipeline and strategic pharma partnerships – watch for earnings and clinical milestones that could lift the stock above its 200‑day average.